2023 World Conference on Lung Cancer (Posters)-EP12.01. Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC

EP12.01. Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the prognostic value of sequential liquid biopsy (LB) after Osimertinib treatment in Hispanic patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). The researchers conducted a retrospective study, including 64 patients who underwent molecular profiling of tumor tissue and collected plasma samples at 8 and 24 weeks after starting Osimertinib. The patients had a mean age of 66 years, with 65% being women and 98.4% having adenocarcinomas. The study found that cfDNA (circulating free DNA) was positive in 42.2% of cases at week 8 and in 22% at week 24. Patients with the L858R mutation and multiple mutations had higher rates of cfDNA positivity. They also observed that cfDNA positivity at weeks 8 and 24 was associated with worse progression-free survival (PFS) and overall survival (OS) compared to patients without cfDNA positivity. The multivariate analysis further confirmed that cfDNA positivity at both timepoints had a negative impact on OS, as did a lack of overall response to Osimertinib. The findings suggest that ctDNA monitoring during Osimertinib treatment can identify a subgroup of patients with poor prognosis who might benefit from adaptive therapy.

Asset Subtitle

Andres Cardona

Meta Tag

Speaker Andres Cardona

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

liquid biopsy

Osimertinib treatment

Hispanic patients

EGFR-mutant non-small cell lung cancer

prognostic value

molecular profiling

cfDNA positivity

progression-free survival

overall survival

adaptive therapy